Volrustomig Priming Regimens Exploratory Phase II Platform Study - eVOLVE-01

Inclusion Criteria

• - Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 with no deterioration.
• - Life expectancy greater than or equal to (>=) 12 weeks.
• - Adequate organ and bone marrow function.
• - Body weight greater than (>) 35 kilograms (kg) at screening and at randomization.
• - Histologically or cytologically documented NSQ NSCLC.
• - Absence of sensitizing epidermal growth factor receptor (EGFR) mutations.
• - Absence of documented tumor genomic alteration results from tests conducted as part of standard local practice in any other actionable driver oncogenes for which there are locally approved targeted 1L therapies.
• - At least one measurable lesion not previously irradiated that can be accurately measured at baseline as >= 10 millimeter (mm) in the longest diameter.